Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group.
We modified the World Federation of Neurology (WFN) diagnostic criteria for ALS to facilitate early diagnosis and used these criteria for enrollment of ALS patients in a clinical trial. The criteria developed required lower motor neuron (LMN) involvement in at least two limbs and upper motor neuron involvement in at least one region (bulbar, cervical, or lumbosacral). The EMG finding of fibrillation potentials was required for evidence of LMN involvement. Electrodiagnostic studies, neuroimaging, and laboratory studies were also used to exclude disorders that might mimic ALS. Using these criteria, the diagnosis of ALS was made at a mean time of 9.7 months from onset of symptoms, which compares favorably with the 12-month period cited in the literature. Using clinical assessment at completion of the trial, the diagnosis of ALS was believed to be accurate in those patients entered in the trial. However, pathologic confirmation of the diagnosis of ALS was not obtained. Based on our preliminary experience, we propose that these ALS diagnostic criteria will facilitate early diagnosis of ALS. Future studies should prospectively compare these criteria with the WFN criteria currently in use.
Ross
M A
MA
Miller
R G
RG
Berchert
L
L
Parry
G
G
Barohn
R J
RJ
Armon
C
C
Bryan
W W
WW
Petajan
J
J
Stromatt
S
S
Goodpasture
J
J
McGuire
D
D
D000690:Amyotrophic Lateral Sclerosis / Q000175:diagnosis* / Q000188:drug therapy; D020934:Ciliary Neurotrophic Factor; D002986:Clinical Trials as Topic; D006801:Humans; D007391:International Cooperation; D009419:Nerve Tissue Proteins / Q000627:therapeutic use; D009462:Neurology / Q000379:methods*; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D013997:Time Factors
D020934:Ciliary Neurotrophic Factor; D009419:Nerve Tissue Proteins; D011994:Recombinant Proteins